Wataru Kawahata is responsible for medicinal chemistry. He has more than 20 years experience in drug discovery research. Prior to joining to PRISM BioLab, he was at Asahi Kasei Pharma for GPCR projects, at Carna Bioscience for kinase projects. He has led the project from the hit finding stage to preclinical stage and identified two novel kinase inhibitors, which are in clinical trials, one for an immuno disease, and the other for a hematologic cancer.He received his MS from Kyushu University, and Ph.D. from Osaka Prefecture University.